COVID-19 Vaccines - Big Pharma and Biotech Race to make Vaccines available by the end of 2020

COVID-19 Vaccines - Big Pharma and Biotech Race to make Vaccines available by the end of 2020


The demand for a vaccine for the COVID-19 virus continues to grow, as the global pandemic continues to impact the lives of billions of people worldwide. The number of deaths globally caused by the virus exceeds 600,000, while economies continue to struggle with the economic turmoil caused by travel restrictions, business closures, and social lockdowns as consequences of the pandemic. Recession is imminent for the global economy. However, some hope has emerged as a handful of research institutions and pharmaceutical corporations and regulatory authorities accelerate their efforts into providing a vaccine for the novel coronavirus. Tracking the progression of these potential vaccines is important, giving a rough indication of when lockdowns can be lifted more safely and social distancing can be relaxed, allowing business to operate as usual without fear for public health.

Key Highlights
- AstraZeneca has formed an alliance with the University of Oxford to assist in the development, manufacturing, marketing and distribution of a potential COVID-19 Vaccination. The company plan on supplying 2 billion doses through 2020 and 2021 and has established a strong manufacturing and distribution network in collaboration with a number of global organizations to help the company deliver its targets effectively. In terms of vaccine development, the University of Oxford candidate is one of the most advanced having reported strong efficacy and safety results from its ongoing UK based Phase I/II clinical trial results on July 20. The group now focus on Phase III trials in Brazil and South Africa to prove the vaccine is able to cause immunity across large populations safely and effectively. If successful AstraZeneca will be the worlds primary supplier of COVID-19 vaccines
- Chinese vaccine manufacturer, Sinovac is also close to gaining regulatory approval of its own COVID-19 vaccine. The company has also initiated Phase III clinical trials in Brazil having reported positive outcomes from previous clinical trials completed on a small population of 743 healthy volunteers, aged from 18 to 59 years. Although the company is optimistic about its ability to produce a valid COVID-19 vaccine, there are concerns over the groups production and distribution capabilities. If its candidate vaccine is approved, the company will struggle to meet global vaccine demands. Government support will help Sinovac increase its manufacturing capabilities, but output will remain well below AstraZeneca estimates of production.
- The BCG vaccine, traditionally used to prevent tuberculosis, is the only other vaccine undergoing phase III clinical trials for COVID-19 in July 2020. However, trials will only test for the vaccines ability to produce a non-specific immune response and if this will help weaken the severity of the virus. The research could benefit key workers, who are at higher risk of infection, by increasing their tolerability until a specific vaccine becomes available. Vaccines at a less advanced stages of development offer an alternative to the vaccines currently undergoing Phase III testing. If phase III trials dont demonstrate the vaccine is efficient and safe enough to use globally, vaccines being developed by the likes of BioNTech, Valneva, Moderno, CanSino and the Wuhan Institute of Biological Products will become the most promising candidates.


- Examine the race to achieve a new vaccine
- See who are the leaders and what possible companies and groups are managing them
- Examine the plans for production and compare approaches

Reasons to Buy

- What vaccine groups are ahead in the race to produce a vaccine?
- How many are likely to achieve their goal?
- Who has the biggest production plans?
- What different approaches are being taken?

1.1. Catalyst
1.2. Summary
2.1. Regulators accelerate COVID-19 vaccine development
2.2. AstraZeneca own most advanced vaccine candidate at present
2.2.1. AstraZeneca prepares a global vaccine supply chain
2.3. Sinovac Candidate vaccines looks positive
2.4. Old tuberculosis vaccine could help in the fight against COVID-19
2.5. BioNTech and Pfizer join Phase III frontrunners with mRNA vaccine
2.6. Alternative options are needed if Phase III trials dont perform.
3.1. Abbreviations and acronyms
3.2. Further reading

List Of Tables

Table 1: COVID-19 candidate vaccines stage of development

List Of Figures

Figure 1: COVID-19 candidate vaccines stages of development July 2020
Figure 2: Astra Zeneca vaccine candidate timeline, 2020
Figure 3: Sinovac SARS-CoV-2 vaccine
Figure 4: Vaccine developers by stage of development

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 Update

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2021 UpdateThis 62-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is

USD 1495 View Report

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021

Coronavirus Disease 2019 (COVID-19) Clinical and Commercial Analyzer - September 15, 2021When faced with an outbreak of a pathogen with no known treatments, we are forced to rely on the

USD 2495 View Report

Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026

Coronavirus Disease 2019 (COVID-19) Vaccines - Opportunity Assessment and Forecast to 2026 market research report available in single user pdf license with Aarkstore Enterprise at USA 10995

USD 10995 View Report

India COVID-19 Vaccines Market – Growth, Demand, Trends, Opportunity, Forecasts (2021 – 2027)

Indias COVID-19 vaccines market is anticipated to grow over US$ 2.3 Billion by 2027 with an impressive CAGR of more than 25% during the forecast period. market research report available in single user pdf license with Aarkstore Enterprise at USD 1190

USD 1190 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available




Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.